Clinical trial
Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
NCT00363766 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00363766 |
|---|---|
| Title | Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer |
| Official title | A Phase 2 Study of LY573636-Sodium Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Third-line Treatment in Patients With Unresectable, Metastatic Non-Small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | LY573636-sodium |
| Enrollment | 52 |
| Start date | Sep 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Aug 15, 2006 |
| Last update posted | Oct 19, 2018 |
| Countries | Germany, Italy |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: